ARCA biopharma, Inc. (ABIO)
NASDAQ: ABIO · IEX Real-Time Price · USD
3.400
+0.150 (4.62%)
At close: Apr 19, 2024, 4:00 PM
3.260
-0.140 (-4.12%)
After-hours: Apr 19, 2024, 7:31 PM EDT
Company Description
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases.
Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial.
ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ARCA biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | C. Jeffrey Dekker CPA |
Contact Details
Address: 10170 Church Ranch Way, Suite 100 Westminster, Colorado 80021 United States | |
| Phone | (720) 940-2200 |
| Website | arcabio.com |
Stock Details
| Ticker Symbol | ABIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000907654 |
| CUSIP Number | 00211Y506 |
| ISIN Number | US00211Y5069 |
| Employer ID | 36-3855489 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| C. Jeffrey Dekker CPA | Chief Financial Officer, Treasurer and Company Secretary |
| Thomas A. Keuer | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 3, 2024 | 425 | Filing |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |